JP6594438B2 - 改善されたｉｌ−６抗体 - Google Patents

改善されたｉｌ−６抗体 Download PDF

Info

Publication number
JP6594438B2
JP6594438B2 JP2017543332A JP2017543332A JP6594438B2 JP 6594438 B2 JP6594438 B2 JP 6594438B2 JP 2017543332 A JP2017543332 A JP 2017543332A JP 2017543332 A JP2017543332 A JP 2017543332A JP 6594438 B2 JP6594438 B2 JP 6594438B2
Authority
JP
Japan
Prior art keywords
antibody
antigen
seq
binding fragment
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017543332A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017535285A (ja
JP2017535285A5 (enExample
Inventor
マイケル マーチ シュミット，
アリソン ティスデール，
エリック スティーブン ファーファイン，
グリゴリオス ザービス−パパストートシス，
Original Assignee
セセン バイオ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セセン バイオ， インコーポレイテッド filed Critical セセン バイオ， インコーポレイテッド
Publication of JP2017535285A publication Critical patent/JP2017535285A/ja
Publication of JP2017535285A5 publication Critical patent/JP2017535285A5/ja
Application granted granted Critical
Publication of JP6594438B2 publication Critical patent/JP6594438B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2017543332A 2014-11-07 2015-11-06 改善されたｉｌ−６抗体 Active JP6594438B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462077105P 2014-11-07 2014-11-07
US62/077,105 2014-11-07
US201462087448P 2014-12-04 2014-12-04
US62/087,448 2014-12-04
US201562247705P 2015-10-28 2015-10-28
US62/247,705 2015-10-28
PCT/US2015/059532 WO2016073890A1 (en) 2014-11-07 2015-11-06 Improved il-6 antibodies

Publications (3)

Publication Number Publication Date
JP2017535285A JP2017535285A (ja) 2017-11-30
JP2017535285A5 JP2017535285A5 (enExample) 2018-12-13
JP6594438B2 true JP6594438B2 (ja) 2019-10-23

Family

ID=54602042

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017543332A Active JP6594438B2 (ja) 2014-11-07 2015-11-06 改善されたｉｌ−６抗体

Country Status (32)

Country Link
US (3) US11142571B2 (enExample)
EP (3) EP3632931A1 (enExample)
JP (1) JP6594438B2 (enExample)
KR (2) KR102636726B1 (enExample)
CN (1) CN107249631B (enExample)
AU (1) AU2015342882B2 (enExample)
CA (1) CA2965689C (enExample)
CL (1) CL2017001135A1 (enExample)
CO (1) CO2017005404A2 (enExample)
CR (1) CR20170231A (enExample)
DK (2) DK3215530T3 (enExample)
EA (1) EA035199B1 (enExample)
ES (2) ES2756275T3 (enExample)
FI (1) FI4268843T3 (enExample)
HR (2) HRP20251312T1 (enExample)
HU (1) HUE046181T2 (enExample)
IL (1) IL251858B (enExample)
LT (1) LT4268843T (enExample)
MA (2) MA51554A (enExample)
MX (2) MX385206B (enExample)
MY (1) MY185114A (enExample)
PE (1) PE20171107A1 (enExample)
PH (1) PH12017500809B1 (enExample)
PL (2) PL3215530T3 (enExample)
PT (2) PT4268843T (enExample)
RS (2) RS59805B1 (enExample)
SA (1) SA517381458B1 (enExample)
SG (2) SG11201703574VA (enExample)
SI (1) SI3215530T1 (enExample)
UA (1) UA122673C2 (enExample)
WO (1) WO2016073890A1 (enExample)
ZA (1) ZA201702985B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI748962B (zh) 2015-09-23 2021-12-11 美商建南德克公司 抗ｖｅｇｆ抗體之最佳化變異體
EP3419599A4 (en) * 2016-02-23 2019-09-11 Sesen Bio, Inc. IL-6 ANTAGONIST FORMULATIONS AND USE THEREOF
US20200347143A1 (en) * 2016-12-19 2020-11-05 Glenmark Pharmaceuticals S.A. Novel tnfr agonists and uses thereof
SG11201908547VA (en) 2017-03-22 2019-10-30 Genentech Inc Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
MX2019011141A (es) 2017-03-22 2019-11-05 Genentech Inc Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares.
CN109867723B (zh) * 2017-12-05 2022-06-17 南京金斯瑞生物科技有限公司 抗人il6单克隆抗体及其制备方法和用途
BR112022018254A2 (pt) 2020-03-13 2022-10-25 Genentech Inc Anticorpos isolados, ácido nucleico isolado, vetor ou conjunto de vetores, célula hospedeira, métodos para produzir um anticorpo, para tratar um distúrbio e para tratar ag em um paciente, composição e uso de um anticorpo
WO2021194913A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Tie2-binding agents and methods of use
WO2022079161A1 (en) 2020-10-15 2022-04-21 F. Hoffmann-La Roche Ag Non-covalent protein-hyaluronan conjugates for long-acting ocular delivery
CN114525235B (zh) * 2022-02-25 2023-07-14 郑州大学 一种提高人表皮生长因子分泌生产效率的方法
CN115343483B (zh) * 2022-08-12 2024-11-26 苏州邦器生物技术有限公司 一种自身免疫性糖尿病检测用试剂盒及其制备方法
CN120112551A (zh) * 2022-10-24 2025-06-06 豪夫迈·罗氏有限公司 预测对il-6拮抗剂的反应

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4548990A (en) 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
DE69233769D1 (de) 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
ATE269401T1 (de) 1991-04-10 2004-07-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE69229477T2 (de) 1991-09-23 1999-12-09 Cambridge Antibody Technology Ltd., Melbourn Methoden zur Herstellung humanisierter Antikörper
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
FR2734739B1 (fr) 1995-06-01 1997-07-11 Gec Alsthom Stein Ind Dispositif de surveillance d'un broyeur a boulets
TW311927B (enExample) 1995-07-11 1997-08-01 Minnesota Mining & Mfg
EP0795743A3 (en) 1996-03-15 1998-02-25 Japan Tobacco Inc. Method and apparatus for infra-red moisture measurement
US5839430A (en) 1996-04-26 1998-11-24 Cama; Joseph Combination inhaler and peak flow rate meter
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ES2246069T3 (es) 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
US6358058B1 (en) 1998-01-30 2002-03-19 1263152 Ontario Inc. Aerosol dispensing inhaler training device
DE69941267D1 (de) 1998-12-10 2009-09-24 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
JP4093757B2 (ja) 1999-08-24 2008-06-04 メダレックス， インコーポレイテッド ヒトｃｔｌａ−４抗体およびその使用
WO2002043478A2 (en) 2000-11-30 2002-06-06 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
DE60236861D1 (de) 2001-04-26 2010-08-12 Amgen Mountain View Inc Kombinatorische bibliotheken von monomerdomänen
ES2392073T3 (es) 2001-11-08 2012-12-04 Abbott Biotherapeutics Corp. Formulación farmacéutica líquida estable de anticuerpos IGG
JP2005532313A (ja) 2002-05-07 2005-10-27 コントロール・デリバリー・システムズ・インコーポレイテッド 薬物送達装置の形成方法
WO2004045507A2 (en) * 2002-11-15 2004-06-03 Centocor, Inc. Anti-angiogenic uses of il-6 antagonists
KR20070001932A (ko) 2003-12-23 2007-01-04 리나트 뉴로사이언스 코퍼레이션 작용물질 항 티알케이씨 항체 및 그의 사용 방법
CA2573192C (en) 2004-08-04 2013-09-10 Applied Molecular Evolution Inc. Variant fc regions
JP2008511337A (ja) 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッド ヘテロ多量体分子
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
EA200870130A1 (ru) * 2005-12-30 2009-02-27 Мерк Патент Гмбх Антитела против ил-6, предотвращающие связывание с gp130 комплекса ил-6 и альфа-рецептора ил-6
CA2644405A1 (en) 2006-03-13 2007-09-20 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
DK2021463T3 (en) 2006-05-19 2017-01-16 Alder Biopharmaceuticals Inc Culture method to obtain a cloned population of antigen-specific B cells
EP2164514B1 (en) * 2007-05-21 2016-12-14 AlderBio Holdings LLC Antibodies to il-6 and use thereof
PT2198007T (pt) 2007-09-14 2018-01-29 Sanofi Pasteur Biologics Llc Composições farmacêuticas contendo toxoides a e b de clostridium difficile
BRPI0820387A2 (pt) 2007-11-21 2015-05-26 Amgen Inc Agentes de ligação de wise e epítopos
US20100187601A1 (en) 2007-12-12 2010-07-29 Fujio Masuoka Semiconductor device
EP2249809A1 (en) 2008-01-15 2010-11-17 Abbott GmbH & Co. KG Powdered protein compositions and methods of making same
CN102170906B (zh) 2008-08-05 2014-07-30 诺华股份有限公司 靶定补体蛋白c5的抗体的组合物和方法
US8657211B2 (en) 2008-09-12 2014-02-25 Kdf Co., Ltd. Water spouting device
US20120005773A1 (en) 2008-10-01 2012-01-05 Aasen Eric D Transgenic plants with enhanced agronomic traits
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
BRPI0921319A2 (pt) 2008-11-26 2018-10-16 Glaxo Group Ltd composição, método para dispensação de uma composição, e para tratar, prevenir ou diagnosticar uma condição ocular, e, processo para produzir uma composição farmacêutica
CA2749200A1 (en) 2009-01-29 2010-08-05 Michael Bowen Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
KR20130050966A (ko) 2010-07-12 2013-05-16 씨오브이엑스 테크놀로지스 아일랜드 리미티드 다기능적 항체 접합체
NZ702201A (en) 2012-07-13 2018-01-26 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
RU2015119547A (ru) 2012-10-25 2016-12-20 МЕДИММЬЮН, ЭлЭлСи Стабильный низковязкий состав с антителом
KR102149206B1 (ko) * 2012-11-08 2020-08-31 세센 바이오, 아이엔씨. 인터루킨-6의 길항제 및 이의 용도
AU2014286996A1 (en) 2013-07-12 2016-01-07 Iveric Bio, Inc. Methods for treating or preventing ophthalmological conditions
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention

Also Published As

Publication number Publication date
PL4268843T3 (pl) 2025-12-15
PT3215530T (pt) 2019-11-21
EP3215530B9 (en) 2020-09-09
RS59805B1 (sr) 2020-02-28
US20220169719A1 (en) 2022-06-02
ES2756275T9 (es) 2020-10-29
SA517381458B1 (ar) 2020-07-09
CL2017001135A1 (es) 2017-12-15
PE20171107A1 (es) 2017-08-07
SG11201703574VA (en) 2017-05-30
AU2015342882A1 (en) 2017-05-18
MX2017005992A (es) 2017-09-15
IL251858B (en) 2022-09-01
MX385206B (es) 2025-03-14
CA2965689C (en) 2022-03-22
US11142571B2 (en) 2021-10-12
BR112017008672A2 (pt) 2018-03-20
RS67353B1 (sr) 2025-11-28
ES3051832T3 (en) 2025-12-30
MX2021008663A (es) 2021-08-19
CO2017005404A2 (es) 2017-10-31
DK4268843T3 (da) 2025-11-10
EP3215530B1 (en) 2019-08-21
EP4268843B1 (en) 2025-09-03
PT4268843T (pt) 2025-10-31
JP2017535285A (ja) 2017-11-30
ZA201702985B (en) 2019-10-30
MY185114A (en) 2021-04-30
HUE046181T2 (hu) 2020-02-28
MA51554A (fr) 2020-11-18
PH12017500809A1 (en) 2017-10-02
CR20170231A (es) 2017-09-25
SG10202103420PA (en) 2021-05-28
EA201791005A1 (ru) 2017-09-29
HRP20191945T1 (hr) 2020-01-24
EP3215530A1 (en) 2017-09-13
KR102636726B1 (ko) 2024-02-13
US20190194312A1 (en) 2019-06-27
WO2016073890A1 (en) 2016-05-12
US20250059270A1 (en) 2025-02-20
ES2756275T3 (es) 2020-04-27
FI4268843T3 (fi) 2025-11-14
EA035199B1 (ru) 2020-05-14
HRP20251312T1 (hr) 2025-12-05
SI3215530T1 (sl) 2020-02-28
MA62787B1 (fr) 2025-11-28
EP3632931A1 (en) 2020-04-08
CN107249631B (zh) 2021-11-23
EP4268843A2 (en) 2023-11-01
IL251858A0 (en) 2017-06-29
HK1244008A1 (en) 2018-07-27
KR102770849B1 (ko) 2025-02-20
NZ731090A (en) 2024-03-22
DK3215530T3 (da) 2019-11-25
CN107249631A (zh) 2017-10-13
PL3215530T3 (pl) 2020-05-18
KR20170077196A (ko) 2017-07-05
LT4268843T (lt) 2025-11-25
PH12017500809B1 (en) 2023-09-20
EP4268843A3 (en) 2023-12-27
CA2965689A1 (en) 2016-05-12
KR20240023450A (ko) 2024-02-21
AU2015342882B2 (en) 2021-05-20
UA122673C2 (uk) 2020-12-28

Similar Documents

Publication Publication Date Title
US20250059270A1 (en) Il-6 antibodies
US11459386B2 (en) IL-6 antagonists and uses thereof
WO2016073894A1 (en) Therapeutic agents with increased ocular retention
HK40102410A (en) Improved il-6 antibodies
HK40027816A (en) Improved il-6 antibodies
HK1244008B (en) Improved il-6 antibodies
BR112017008672B1 (pt) Anticorpo ou fragmento de ligação ao antígeno, seu uso, fab isolado, composição, e vetor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181030

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181030

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190823

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190821

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190924

R150 Certificate of patent or registration of utility model

Ref document number: 6594438

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250